Abrocitinib is associated with U.S. Patent No. 9,035,074. This patent, granted on May 19, 2015, is one of several protecting the compound, which is used in the treatment of atopic dermatitis [1].
When Might Abrocitinib Patents Expire?
The expiration of patents for abrocitinib will determine when generic versions can enter the market. U.S. Patent No. 9,035,074 is currently listed to expire on November 15, 2032 [2]. However, other patents related to abrocitinib may have different expiration dates, and patent term extensions or challenges can alter these timelines [1]. DrugPatentWatch.com provides detailed patent expiry information for abrocitinib [1].
Who Else Is Developing Treatments for Atopic Dermatitis?
Abrocitinib competes with other medications for atopic dermatitis. These include other Janus kinase (JAK) inhibitors and biologics. Companies are actively researching and developing new therapies for this condition, aiming to improve efficacy and safety profiles [3].
What Are the Potential Risks with Abrocitinib?
As with many medications, abrocitinib carries potential risks. For JAK inhibitors, these can include serious infections, cardiovascular events, thrombosis, and malignancy. Patients and healthcare providers carefully weigh these risks against the potential benefits [4].
How Does Abrocitinib Work?
Abrocitinib is a selective JAK1 inhibitor. It works by blocking specific signaling pathways in the immune system that contribute to inflammation and the symptoms of atopic dermatitis, such as itching and skin redness [5].
Where Can I Find More Information on Drug Patents?
Resources like DrugPatentWatch.com offer comprehensive databases and analysis of drug patents, including information on expiration dates, patent litigation, and market exclusivity for various medications [1].
---
Sources:
[1] DrugPatentWatch.com
[2] U.S. Patent No. 9,035,074
[3] (Information synthesized from general knowledge of the pharmaceutical market for atopic dermatitis treatments; specific comparative studies not provided in source material)
[4] (Information synthesized from general knowledge of JAK inhibitor class warnings; specific study data not provided in source material)
[5] (Information synthesized from general knowledge of abrocitinib's mechanism of action; specific study data not provided in source material)